Abatacept for the treatment of juvenile idiopathic arthritis
 
Status Discontinued
Process STA pre-2018
Referral date 01 June 2008
Topic area
  • Musculoskeletal

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC

Consultees

Manufacturers/sponsors Bristol Myers Squibb Pharmaceuticals (abatacept)
Others Cardiff LHB
  Department of Health
  Doncaster PCT
  Welsh Assembly Government
Patient/carer groups Action for Children
  Action for Sick Children
  Action on Pain
  Afiya Trust
  Arthritic Association
  Arthritis and Musculoskeletal Alliance (ARMA)
  Arthritis Care
  BackCare
  Black Health Agency
  British Ethnic Health Awareness Foundation (BEHAF)
  Children’s Society
  Children’s Chronic Arthritis Association
  Chinese National Healthy Living Centre
  Confederation of Indian Organisations
  Equalities National Council
  Leonard Cheshire Disability
  Muslim Council of Great Britain
  Muslim Health Network
  National Children’s Bureau
  National Parent and Carer Council
  National Parent Partnership Network
  National Rheumatoid Arthritis Society
  Pain Concern
  Pain Relief Foundation
  RADAR - Royal Association for Disability and Rehabilitation
  Skill: National Bureau for Students with Disabilities
  South Asian Health Foundation
  Specialised Healthcare Alliance
  WellChild
Professional groups British Health Professionals in Rheumatology
  British Institute of Musculoskeletal Medicine
  British Orthopaedic Association
  British Pain Society
  British Society for Paediatric and Adolescent Rheumatology
  British Society for Rheumatology
  British Society of Rehabilitation Medicine
  College of Occupational Therapists
  Physiotherapy Pain Association
  Primary Care Rheumatology Society
  Rheumatoid Arthritis Surgical Society
  Royal Society of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Paediatrics & Child Health
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine – Intellectual Disabilities Forum
  United Kingdom Clinical Pharmacy Association

Commentators

Associated Guideline Groups National Clinical Guidelines Centre for Acute and Chronic Conditions
Associated Public Health Groups None
Comparator manufacturer(s) Abbott Pharmaceuticals (adalimumab)
  Generics (UK) (sulfasalazine)
  IVAX Pharmaceuticals (sulfasalazine)
  Mayne Pharma (methotrexate)
  Medac UK (methotrexate)
  Novartis Pharmaceuticals (ciclosporin)
  Pfizer (sulfasalazine, methotrexate)
  Sanofi Aventis (hydroxychloroquine, leflunomide)
  Schering-Plough (infliximab)
  Teva UK (sulfasalazine)
  Wockhardt UK (methotrexate)
  Wyeth Laboratories (etanercept)
Evidence Review Group NHS Centre for Reviews & Dissemination and Centre for Health Economics –York
  National Institute for Health Research Health Technology Assessment Programme
General Board of Community Health Councils in Wales
  British National Formulary
  Department of Health,Social Services and Public Safety for Northern Ireland
  Medicines and Healthcare products Regulatory Agency (MHRA)
  National Association of Primary Care
  National Public Health Service for Wales
  NHS Alliance
  NHS Confederation
  NHS Purchasing and Supply Agency
  NHS Quality Improvement Scotland
  Scottish Medicines Consortium
Relevant research groups Arthritis Research Campaign
  Bone Research Society
  MRC Clinical Trials Unit
  National Institute of Health Research
  United Kingdom Clinical Research Network

Timeline

Key events during the development of the guidance:

Date Update
7 August 2009 The above topic was referred to NICE as part of the 17th wave referrals. The manufacturer of abatacept has informed us that they are not in a position to submit evidence in line with the current schedule for this STA because of a delay in the regulatory process. This STA is therefore suspended.
7 July 2010 The marketing authorisation for abatacept in this therapeutic area suggests limited use of this drug for a small population of those with juvenile idiopathic arthritis. Following discussions with the Department of Health, we have therefore concluded that this topic should be removed from the work programme.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance